Do you have the same question? Follow this Question
May 13, 2026 - 08:31 AM
We’ve provided several answers to questions related to Vyepti (Eptinezumab) , see some other helpful Q&A related to this product.
Question: What are the unique identifiers for this medication in medical databases?
Answer: The unique identifiers are PubChem CID: 123844991, MedlinePlus: a620036, ChEBI: 183098, ATC code: N02CD06, DrugBank: DB15110, and KEGG: D11917. These identifiers are valuable for healthcare professionals and researchers referencing this medication across global databases.
Question: Is this product suitable for people with kidney or liver problems?
Answer: No dose adjustment is necessary for patients with renal (kidney) or hepatic (liver) impairment. This feature provides value by simplifying dosing and making the product accessible to a wider range of patients.
Question: What is the elimination half-life of the medication?
Answer: The elimination half-life is 27 days. A long half-life allows for infrequent dosing, making it more convenient for patients and supporting sustained migraine prevention.
